THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today released the evaluation of the microscopic assessment of tissues from a six-month mouse study conducted to satisfy a portion of the FDA mandated two-species trials to demonstrate the lack of carcinogenic potential for new chemical entities. In this positive and negative controlled study, Proellex showed no microscopic evidence for tumor induction as compared to both controls. Proellex was tested at 10, 40 and 100 times the human dose in this well-recognized and -characterized study. Previously, the Company reported that the positive control, urethane, yielded easily identifiable tumors on gross necropsy while none were observed in the Proellex treated animals.
